New hope for AML patients who relapse after standard treatment
NCT ID NCT07304011
Summary
This study tests whether a drug combination can help control acute myeloid leukemia (AML) in patients with a specific genetic mutation (IDH1) who have already received standard treatment. The trial involves 28 adults who responded to prior therapy but need additional treatment. Participants receive olutasidenib pills plus azacitidine injections, followed by olutasidenib alone, to see if this approach can keep the cancer from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.